openPR Logo
Press release

Synovial Sarcoma Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

09-23-2024 05:55 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Synovial Sarcoma Market

Synovial Sarcoma Market

The Synovial Sarcoma market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc.

[Nevada, United States] - DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Synovial Sarcoma, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Synovial Sarcoma Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Synovial Sarcoma Market Report:
The Synovial Sarcoma market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In July, 2024: Epizyme, Inc.announced that their study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
In April, 2024: Adaptimmune announced that a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers
In July, 2024: Adaptimmune announced that their trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Synovial sarcoma is a rare cancer, with an incidence rate of approximately 1.5-2.75 cases per million people per year globally. In the United States, this equates to around 900-1,000 new cases annually.
In the 7MM, the total incident cases of synovial sarcoma in 2023 were ~1,600 out of which the highest cases of this disease were seen in the United States
The incidence of synovial sarcoma has been estimated to be very low and rare, accounting for only 5-10% of all soft tissue sarcoma. This means a small patient target for new entrants.
Key Synovial Sarcoma Companies are as follows: Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc.
Key Synovial Sarcoma Therapies are as follow: Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, IMC-A12, soblidotin, Doxorubicin, APX005M, pazopanib, Tazemetostat
Launching multiple stage Synovial Sarcoma pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Synovial Sarcoma market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Synovial Sarcoma Overview:
Synovial sarcoma is cancer that can originate from different types of soft tissue, such as muscle or ligaments. It is often found inthe arm, leg, or foot and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen. Synovialsarcoma may also be called malignant synovioma. It accounts for 5-10% of soft-tissue tumors. For every one million people, oneto two are diagnosed with synovial sarcoma per year in the US.

Synovial Sarcoma Epidemiology Segmentation:
The Synovial Sarcoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Incident Cases of Synovial Sarcoma
Location-specific Cases of Synovial Sarcoma
Antigens-specific (MAGE-A4, NY-ESO-1, PRAME, and others) Cases of Synovial Sarcoma
Age-specific Cases of Synovial Sarcoma
Stage-specific Cases of Synovial Sarcoma
Gender-specific cases of Synovial Sarcoma

For more information about Synovial Sarcoma companies working in the treatment market, visit https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Synovial Sarcoma Market Insights
Synovial sarcoma is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4. The hybrid transcriptionfactor SS18: SSX alters SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling and global methylation patternsthat may allow for future therapeutic opportunities.

Synovial Sarcoma Drugs Uptake
Trabectedin (VOTRIENT), an antitumor agent is approved in Europe for the treatment of adult patients withadvanced soft tissue sarcoma after failure of anthracyclines (doxorubicin) and ifosfamide, or those who are unfit toreceive these agents whereas in US, it has been approved for specific types of STS but its utility as a therapeutictreatment for synovial sarcoma is uncertain
Pazopanib (ONDELIS) is an oral multitarget tyrosine kinase inhibitor (TKI) with a clinical antitumor effect that is thoughtto be exerted through its selective inhibition of vascular endothelial growth factor receptor (VEGFR)-mediatedangiogenesis, as well as its direct blockade of growth-promoting receptor tyrosine kinases (RTKs)
As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by awatchful waiting approach to assess the optimum response. Doxorubicin and Ifosfamideconstitute the first lineapproach thereby helping generate a large chunk of the revenue

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Synovial Sarcoma Therapies and Key Companies:
Cyclophosphamide: Takara Bio Inc.
AL3818, Dacarbazine: Advenchen Laboratories, LLC
Sorafenib and Dacarbazine: Memorial Sloan Kettering Cancer Center
IMC-A12: Eli Lilly and Company
soblidotin: Daiichi Sankyo
Doxorubicin, APX005M: Alexander Z. Wei, MD
pazopanib: GlaxoSmithKline
Tazemetostat: Epizyme, Inc.

Synovial Sarcoma Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Synovial Sarcoma.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Synovial Sarcoma Market Drivers:
Advancements in Targeted Therapies
Increased Focus on Biomarkers and Personalized Medicine
Orphan Drug Designation and Regulatory Support
Ongoing Clinical Trials and Emerging Treatments

Synovial Sarcoma Market Barriers:
Rarity of the Disease
High Cost of Emerging Therapies
Limited Therapeutic Options for Advanced Disease
Complexity of Disease and Heterogeneity

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Synovial Sarcoma Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Synovial Sarcoma Companies: Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc.
Key Synovial Sarcoma Therapies: Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, IMC-A12, soblidotin, Doxorubicin, APX005M, pazopanib, Tazemetostat
Synovial Sarcoma Therapeutic Assessment: Current marketed and emerging therapies
Synovial Sarcoma Market Dynamics: Synovial Sarcoma Market drivers and Synovial Sarcoma barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Synovial Sarcoma Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Synovial Sarcoma market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Synovial Sarcoma Market Overview at a Glance
4 Methodology of Synovial Sarcoma Epidemiology and Market
5 Executive Summary of Synovial Sarcoma
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Key Events
9 Patient Journey
10 Marketed Drugs
11 Emerging Products
12 Synovial Sarcoma: Market Analysis
13 Unmet Needs
14 SWOT Analysis
15 KOL Views
16 Market Access and Reimbursement
16.4 Market Access and Reimbursement of synovial sarcoma
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synovial Sarcoma Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034 here

News-ID: 3664622 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Synovial

Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Synovial
Synovial Sarcoma Market Size, Share, Report and Forecast 2024-2032
The synovial sarcoma market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by increasing research activities in targeted therapy development. Synovial Sarcoma: Introduction Synovial sarcoma is a rare and aggressive type of soft tissue cancer, primarily affecting young adults. It often arises near large joints, especially the knees, though it can occur anywhere in the body. Despite its name, it's not related to
Synovial Sarcoma Market Size, Trends, Industry Value and Latest Insights Till 20 …
What is the market size of synovial sarcoma? The synovial sarcoma market reached a value of US$ 75.3 Million in 2023 and expected  to reach US$ 114.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034. Request for a Sample of this Report: https://www.imarcgroup.com/synovial-sarcoma-market/requestsample Synovial Sarcoma Market Trends: Synovial sarcoma is a rare and aggressive form of soft tissue cancer that primarily affects young adults. Despite its rarity, the market for
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size